Chronic EndometritisNCT07488949
Doxycycline and Progestin Therapy for Chronic Endometritis(CE) in Patients With Recurrent Reproductive Failure(RRF)
A study testing Doxycycline combined with Medroxyprogesterone in people with Chronic Endometritis, run by Fang Wang at 1 site in China.
Trial summary
A Prospective Randomized Controlled Trial, the goal of this clinical trial is to evaluate the efficacy and safety of doxycycline alone versus doxycycline plus medroxyprogesterone acetate (MPA) in women with chronic endometritis (CE), and to assess subsequent reproductive outcomes. Read more about this study
- Who is it for?
- Ages 20 to 45 years, women only
- Conditions the study is for
- Chronic Endometritis
- What is being tested?
- Doxycycline combined with Medroxyprogesterone
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 1,000 participants
- Where
- 1 siteChina
- Study dates
- 9 Apr 2024to 31 Dec 2031
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 45 years
- Women only
- No healthy volunteers
- Adult
Who may be able to join
- women aged 20-45 years;
- plans to conceive within 12 months;
- chronic endometritis(CE) confirmed by endometrial CD138 immunohistochemistry (IHC);
- a diagnosis of recurrent reproductive failure(RRF);
- willingness to undergo hysteroscopy and endometrial biopsy;
- no contraindications to the study medications.
Who cannot join
- acute genital tract infection, gynecologic malignancy, endometrial hyperplasia, or uterine fibroids;
- pregnancy or lactation;
- contraindications to hysteroscopy or anesthesia;
- use of antibiotics, glucocorticoids, estrogens, or progestins within 3 months before trial initiation;
- allergy to doxycycline or medroxyprogesterone acetate(MPA);
- abnormal semen parameters in the male partner.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
Lanzhou University Second Hospital
Lanzhou, Gansu, 730030
Fang Wang, 13919302888, ery_fwang@lzu.edu.cn
About this study
Official title: Clinical Efficacy and Pregnancy Outcomes of Doxycycline Combined With Medroxyprogesterone Acetate Therapy for Chronic Endometritis(CE) in Patients With Recurrent Reproductive Failure(RRF): A Prospective Randomized Controlled Trial
A Prospective Randomized Controlled Trial, the goal of this clinical trial is to evaluate the efficacy and safety of doxycycline alone versus doxycycline plus medroxyprogesterone acetate (MPA) in women with chronic endometritis (CE), and to assess subsequent reproductive outcomes. Participants will be randomly assigned to one of two groups and will receive the assigned treatment. Participants will be followed for reproductive outcomes, including pregnancy , ongoing pregnancy, spontaneous miscarriage, and live birth.
- Conditions
- Chronic Endometritis
- Being tested
- Doxycycline combined with Medroxyprogesterone, Doxycycline combined with placebo
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Doxycycline combined with MedroxyprogesteroneDrug
doxycycline 200 mg/day (100 mg twice daily) combined with medroxyprogesterone acetate(MPA) 24 mg/day (8 mg three times daily) for 14 days
Doxycycline combined with placeboDrug
doxycycline 200 mg/day (100 mg twice daily) with placebo 24 mg/day (8 mg three times daily) for 14 days
| Study group | Role | What they receive |
|---|---|---|
| doxycycline combined with medroxyprogesterone acetate(MPA) | Experimental | Not described Receives: Drug: Doxycycline combined with Medroxyprogesterone |
| doxycycline combined with placebo | Active comparator | Not described Receives: Drug: Doxycycline combined with placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Cure rate of chronic endometritis
Measured: At 8 weeks after completion of treatment
Secondary outcomes (4)
pregnancy rate
Pregnancy was defined as a pregnancy confirmed after completion of treatment, including biochemical pregnancy. Only the first pregnancy after completion of treatment was included in the analysis.
Measured: From completion of treatment to the end of the follow-up period, with a minimum follow-up of 6 months.
Live birth rate
Live birth was defined as delivery of a live infant at or beyond 24 weeks of gestation. Only the first pregnancy after completion of treatment was included in the analysis.
Measured: From completion of treatment to the end of follow-up, with a minimum follow-up of 6 months
Rate of pregnancy loss
Pregnancy loss was defined as spontaneous loss of a pregnancy before 24 weeks of gestation. Only the first pregnancy after completion of treatment was included in the analysis.
Measured: From completion of treatment to the end of follow-up, with a minimum follow-up of 6 months
sustained pregnancy rate
Sustained pregnancy was defined as a pregnancy lasting for at least 12 weeks of gestation. Only the first pregnancy after completion of treatment was included in the analysis.
Measured: From completion of treatment to the end of follow-up, with a minimum follow-up of 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Mar 2026
- Study start9 Apr 2024
- Primary completion31 Dec 2030 (estimated)
- Study completion31 Dec 2031 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Chronic EndometritisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Outcomes assessor
- Enrolment
- 1,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Fang Wang
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Fang Wang, Lanzhou University Second Hospital
- Investigators
- Fang Wang, Principal investigator, Lanzhou University Second Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07488949
- Sponsor's protocol ID
- 2023A-740
- Status last verified
- Mar 2026
- First submitted
- 12 Mar 2026
- Last updated
- 23 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 23 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Clinical Efficacy and Pregnancy Outcomes of Doxycycline Combined With Medroxyprogesterone Acetate Therapy for Chronic Endometritis(CE) in Patients With Recurrent Reproductive Failure(RRF): A Prospective Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT07488949
- Acronym / sponsor ID
- 2023A-740
- Conditions
- Chronic Endometritis
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 1,000 participants (estimated)
- Lead sponsor
- Fang WangUniversity, hospital or other
- Study start
- 9 Apr 2024 (actual)
- Primary completion
- 31 Dec 2030 (estimated)
- Study completion
- 31 Dec 2031 (estimated)
- First posted
- 23 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A Prospective Randomized Controlled Trial, the goal of this clinical trial is to evaluate the efficacy and safety of doxycycline alone versus doxycycline plus medroxyprogesterone acetate (MPA) in women with chronic endometritis (CE), and to assess subsequent reproductive outcomes. Participants will be randomly assigned to one of two groups and will receive the assigned treatment. Participants will be followed for reproductive outcomes, including pregnancy , ongoing pregnancy, spontaneous miscarriage, and live birth.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| doxycycline combined with medroxyprogesterone acetate(MPA) | Experimental | Drug: Doxycycline combined with Medroxyprogesterone |
| doxycycline combined with placebo | Active comparator | Drug: Doxycycline combined with placebo |
Who may qualify
- Ages
- 20 to 45 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (6 listed)
- women aged 20-45 years;
- plans to conceive within 12 months;
- chronic endometritis(CE) confirmed by endometrial CD138 immunohistochemistry (IHC);
- a diagnosis of recurrent reproductive failure(RRF);
- willingness to undergo hysteroscopy and endometrial biopsy;
Key exclusion criteria (6 listed)
- acute genital tract infection, gynecologic malignancy, endometrial hyperplasia, or uterine fibroids;
- pregnancy or lactation;
- contraindications to hysteroscopy or anesthesia;
- use of antibiotics, glucocorticoids, estrogens, or progestins within 3 months before trial initiation;
- allergy to doxycycline or medroxyprogesterone acetate(MPA);
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Doxycycline combined with Medroxyprogesteronedoxycycline 200 mg/day (100 mg twice daily) combined with medroxyprogesterone acetate(MPA) 24 mg/day (8 mg three times daily) for 14 days | Drug | doxycycline combined with medroxyprogesterone acetate(MPA) |
| Doxycycline combined with placebodoxycycline 200 mg/day (100 mg twice daily) with placebo 24 mg/day (8 mg three times daily) for 14 days | Drug | doxycycline combined with placebo |
Primary outcome
Cure rate of chronic endometritis
Time frame: At 8 weeks after completion of treatment
4 secondary outcomes
pregnancy rate
Time frame: From completion of treatment to the end of the follow-up period, with a minimum follow-up of 6 months.
Live birth rate
Time frame: From completion of treatment to the end of follow-up, with a minimum follow-up of 6 months
Rate of pregnancy loss
Time frame: From completion of treatment to the end of follow-up, with a minimum follow-up of 6 months
sustained pregnancy rate
Time frame: From completion of treatment to the end of follow-up, with a minimum follow-up of 6 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Mar 2026.
Related trials for Chronic Endometritis
Not yet recruitingObservational study
Hysteroscopy and CD138+ Plasma Cell Density in Chronic Endometritis
Chronic Endometritis
Not yet recruitingPhase 4
Cyclobenzaprine for Postoperative Pain in Minimally Invasive Hysterectomy
Minimally Invasive Surgical Procedures, Abnormal Uterine Bleeding, Unspecified
Not yet recruitingObservational study
GnRH Agonist Pretreatment in Persistent Chronic Endometritis Undergoing FET
Chronic Endometritis
RecruitingObservational study
Fertility Outcomes After Antibiotic Treatment In Women With Chronic Endometritis
Endometritis, Infertility
RecruitingObservational study
The FLORA-project: in Search for the Microbial Cause of Chronic Endometritis and the Most Appropriate Treatment to Obtain a Successful Pregnancy IVF/ICSI
Endometritis; Chronic, Subfertility
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Fang Wang principal investigator
Lanzhou University Second Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Doxycycline combined with Medroxyprogesterone in people with Chronic Endometritis, run by Fang Wang at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 23 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Fang Wang (13919302888, ery_fwang@lzu.edu.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Cure rate of chronic endometritis (time frame: At 8 weeks after completion of treatment). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Mar 2026.